BioMedNewsBreaks – BioMedWire to Serve as Official Newswire for FWD Pharma Conference and Strategic HCP Partnerships Summit

BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of many brands part of the InvestorBrandNetwork (“IBN”), today announced its collaboration with the FWD Pharma Conference, scheduled to be held Aug. 31-Sept. 1, 2020, as well as participation in the Strategic HCP Partnerships Summit, slated for Nov. 18-20, 2020. According to the update, IBN will serve as the official media sponsor and BioMedWire will serve as the official newswire of both events. “We have enjoyed working with the Global Strategic Management Institute on multiple events in the past and are looking forward to continuing that relationship,” Jonathan Keim, communications director for InvestorBrandNetwork, stated in the news release. “FWD Pharma has an impressive approach to joining industry professionals with interactive panels, case studies and hands-on workshops to help attendees truly understand the importance of today’s digital journey.”

To view the full press release, visit http://ibn.fm/as1PU

About The FWD Pharma Conference

The second annual FWD Pharma is designed to position professionals in the biotech, life sciences, and pharmaceutical industries for success. The three-day, forward-thinking virtual event will educate industry executives on how their organizations can benefit from digital technologies that are reducing costs, improving understanding of market dynamics and strengthening customer loyalty. Hosted by the Lincoln Health Network, the FWD Pharma virtual event is set for Aug. 3–Sept. 1, 2020. For more information, visit www.FWDPharmaConference.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated…

3 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery 

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Bioscience announced key advancements in their global intellectual property portfolio supporting OT-101, a…

3 days ago

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox

NanoViricides, Inc. (NYSE American: NNVC) announced it has filed an application for Orphan Drug Designation…

3 days ago

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer…

4 days ago

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) to Report Fourth-Quarter 2025 Financial Results Feb. 17

Earth Science Tech (OTC: ETST), a strategic holding company focused on acquiring and scaling high-potential…

5 days ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics using proprietary intranasal delivery…

6 days ago